Copner Biotech is a Welsh biotech start up whose state of the art design and manufacturing process enables 3D cell culture scaffolds to be produced based on concentric shape constructs, such as circles. This provides a consistent variability of pore size (heterogenous pore size and distribution) emanating from the centre to the periphery of a scaffold.
Copner Biotech sought ‘wet lab’ and academic support in the form of sterilisation and cellular toxicity testing. Prior to this collaboration with the Accelerate programme, the company could manufacture scaffolds but did not have the ability to perform the testing required.
The collaboration led to the generation of an in vitro data set relating both the appropriate choice of sterilisation method and toxicity profile of the scaffolds.
Jordan Copner, CEO of Copner Biotech said:
"The support from Accelerate has been invaluable, especially to a company that started in a global pandemic.
Obviously, funds were incredibly limited so to have a partner with such expertise, particularly cell culture has been incredible.
The Accelerate programme has helped us to validate our scaffolds in a biological setting. They have conducted multiple cell experiments including scanning electron microscopy and cellular assays. These two together gives Copner Biotech a plethora of data to move forward for commercialisation”.
This project was supported by Accelerate, a now-closed programme led by Life Sciences Hub Wales.
